2-Anilino-4-(benzimidazol-2-yl)pyrimidines ― A multikinase inhibitor scaffold with antiproliferative activity toward cancer cell linesDETERMANN, Renate; DREHER, Jan; BAUMANN, Knout et al.European journal of medicinal chemistry. 2012, Vol 53, pp 254-263, issn 0223-5234, 10 p.Article

Regorafenib: carving a niche in the crowded therapeutic landscapeSIROHI, Bhawna; DEEPA SUSAN PHILIP; SHRIKHANDE, Shailesh V et al.Expert review of anticancer therapy. 2013, Vol 13, Num 4, pp 385-393, issn 1473-7140, 9 p.Article

Preclinical evaluation of the novel multi-targeted agent R1530KOLINSKY, Kenneth; TOVAR, Christian; LIU, Jin-Jun et al.Cancer chemotherapy and pharmacology. 2011, Vol 68, Num 6, pp 1585-1594, issn 0344-5704, 10 p.Article

Dermatologic symptoms associated with the multikinase inhibitor sorafenibROBERT, Caroline; MATEUS, Christina; SPATZ, Alain et al.Journal of the American Academy of Dermatology. 2009, Vol 60, Num 2, pp 299-305, issn 0190-9622, 7 p.Article

A New Spectrum of Skin Toxic Effects Associated With the Multikinase Inhibitor VandetanibGIACCHERO, Damien; RAMACCIOTTI, Constanza; ROBERT, Caroline et al.Archives of dermatology (1960). 2012, Vol 148, Num 12, pp 1418-1420, issn 0003-987X, 3 p.Article

Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cellsPIERRE, Fabrice; REGAN, Collin F; RYCKMAN, David M et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 9, pp 3327-3331, issn 0960-894X, 5 p.Article

Multikinase Inhibitors in Metastatic Renal Cell Carcinoma: Indirect Comparison Meta-AnalysisLEUNG, Henry W. C; CHAN, Agnes L. F.Clinical therapeutics. 2011, Vol 33, Num 6, pp 708-716, issn 0149-2918, 9 p.Article

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism StudiesYAP, Timothy A; ARKENAU, Hendrik-Tobias; LEACH, Martin O et al.Clinical cancer research (Print). 2013, Vol 19, Num 4, pp 909-919, issn 1078-0432, 11 p.Article

Sorafenib use while waiting for liver transplant: We still need to waitFINN, Richard S.Journal of hepatology. 2012, Vol 56, Num 3, pp 723-725, issn 0168-8278, 3 p.Article

Drug Therapy: SorafenibFINN, Richard S.Hepatology (Baltimore, Md.). 2010, Vol 51, Num 5, pp 1843-1849, issn 0270-9139, 7 p.Article

Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptorBROWNLOW, N; MOL, C; HAYFORD, C et al.Leukemia. 2009, Vol 23, Num 3, pp 590-594, issn 0887-6924, 5 p.Article

Profound Inhibition of Antigen-SpecificT-Cell Effector Functions by DasatinibWEICHSEL, Ralf; DIX, Carolin; EINSELE, Hermann et al.Clinical cancer research. 2008, Vol 14, Num 8, pp 2484-2491, issn 1078-0432, 8 p.Article

Sorafenib: Where Do We Go from Here?SIEGEL, Abby B; OLSEN, Sonja K; MAGUN, Arthur et al.Hepatology (Baltimore, Md.). 2010, Vol 52, Num 1, pp 360-369, issn 0270-9139, 10 p.Article

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. CommentaryJOENSUU, Heikki; CHU, Tammy F; DESAI, Jayesh et al.Lancet (British edition). 2007, Vol 370, Num 9604, issn 0140-6736, 1978-1980, 2011-2019 [12 p.]Article

Dasatinib enhances megakaryocyte differentiation but inhibits platelet formationMAZHARIAN, Alexandra; GHEVAERT, Cedric; LIN ZHANG et al.Blood. 2011, Vol 117, Num 19, pp 5198-5206, issn 0006-4971, 9 p.Article

Augmentation of Radiation Response by Motesanib, a Multikinase Inhibitor that Targets Vascular Endothelial Growth Factor ReceptorsKRUSER, Tim J; WHEELER, Deric L; ARMSTRONG, Eric A et al.Clinical cancer research (Print). 2010, Vol 16, Num 14, pp 3639-3647, issn 1078-0432, 9 p.Article

Metabolism and Disposition of Dasatinib after Oral Administration to HumansCHRISTOPHER, Lisa J; DONGHUI CUI; GALBRAITH, Susan et al.Drug metabolism and disposition. 2008, Vol 36, Num 7, pp 1357-1364, issn 0090-9556, 8 p.Article

Dasatinib inhibits proinflammatory functions of mature human neutrophilsFUTOSI, Krisztina; NEMETH, Tamas; PICK, Robert et al.Blood. 2012, Vol 119, Num 21, pp 4981-4991, issn 0006-4971, 11 p.Article

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinibLEE, W. J; LEE, J. L; CHANG, S. E et al.British journal of dermatology (1951). 2009, Vol 161, Num 5, pp 1045-1051, issn 0007-0963, 7 p.Article

Multikinase inhibitors in thyroid cancerLICITRA, Lisa; LOCATI, Laura D; GRECO, Angela et al.European journal of cancer (1990). 2010, Vol 46, Num 6, pp 1012-1018, issn 0959-8049, 7 p.Article

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokineticsSUNAKAWA, Yu; FURUSE, Junji; OKUSAKA, Takuji et al.Investigational new drugs. 2014, Vol 32, Num 1, pp 104-112, issn 0167-6997, 9 p.Article

Safety and Activity of Sorafenib in Different Histotypes of Advanced Renal Cell CarcinomaPROCOPIO, Giuseppe; VERZONI, Elena; GEVORGYAN, Arpine et al.Oncology. 2007, Vol 73, Num 3-4, pp 204-209, issn 0030-2414, 6 p.Article

Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical AspectsPETRILLO, Marco; BORRIELLO, Maddalena; FUOCO, Gilda et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 19, pp 2702-2712, issn 1381-6128, 11 p.Article

Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitorsFAYE, Emmanuelle; BONDON-GUITTON, Emmanuelle; OLIVIER-ABBAL, Pascale et al.European journal of clinical pharmacology. 2013, Vol 69, Num 10, pp 1819-1826, issn 0031-6970, 8 p.Article

Sorafenib: Tolerance in Patients on Chronic Hemodialysis : A Single-Center ExperienceMAROTO REY, Pablo; VILLAVICENCIO, Humberto.Oncology. 2008, Vol 74, Num 3-4, pp 245-246, issn 0030-2414, 2 p.Article